Monday, May 22, 2017

Singapore eDevelopment Ltd (SGX:40V) Cancer and Alzheimer’s Platform

Singapore eDevelopment Ltd (“SeD”), through its subsidiary Global BioLife Inc. (“Global BioLife”), has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer’s, diabetes and cancer. The research will be led by two-time Nobel Prize nominee, Mr Daryl Thompson.

Singapore Exchange-listed SeD said Mr Daryl Thompson will leverage on his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the research and development of this universal therapeutic drug platform, known as Linebacker.

Unlike the traditional approach to cure individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.

Mr Daryl Thompson will lead the research to be conducted by Global BioLife in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD’s wholly-owned subsidiary, Global BioMedical Inc. The remaining stake of Global BioLife is held in equal proportions by Mr Daryl Thompson’s GRDG Sciences LLC and Australia Securities Exchange-listed Holista CollTech Limited.

Mr Daryl Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world’s deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.

No comments:

Post a Comment